Gidi Kahana, CEO
Gidi is an experienced manager in the high-tech field, with background in both the chemical and life-science industries. He is the co-founder of SteadyMed Ltd., a technology-based drug-delivery company, and was the Managing Director of an innovative company specializing in novel delivery mechanisms for oral probiotics (Novobiotec Ltd.), prior to its sale to a US company. Gidi has extensive background in dry-powders and in commercializing novel technology-based processes.
Arie Holtz, VP R&D
Mr. Holtz has been the Chief Operating Officer and Operations Manager of two startup companies in
the medical devices field where he established the companies engineering, manufacturing, and Quality
Assurance facilities. He has also worked extensively in design and process/manufacturing engineering.
Mr. Holtz has an MBA from Heriot-Watt University Edinburgh Business School and a B.Sc. in Mechanical
Engineering from the Technion (Israel Institute of Technology).
Ian Solomon, VP Business Development
Ian is a serial entrepreneur in the high-tech field, specializing in drug packaging and drug delivery. As co-founder of the Profile Group of companies, in recent years he has been involved in the establishment and commercial development of drug-delivery companies in the parenteral, nasal and pulmonary fields. Ian is leading the market definition and industry contacts for Aespira.
Jacob Atsmon, M.D., Clinical Manager
Dr. Atsmon graduated the Tel-Aviv University Sackler School of Medicine, and specialized in Internal Medicine in Israel and Clinical Pharmacology at Vanderbilt University, USA. Since 1997 he has served as the Director of the Early-Phase Research Center (EPRC) at Tel-Aviv’s Sourasky Medical Center and the Head of the Hospital's Clinical Pharmacology Unit. Dr. Atsmon is regarded as one of the leading experts in Israel in conducting early-phase clinical trials and has gained vast experience in this area.